---
title: "Biodexa rises on FDA's 'fast track' tag for rare disease drug"
date: "2025-02-11 00:43:34"
summary: "** U.S.-listed shares of UK-based drugmaker Biodexa's , rise 57% to $6.50** Company says U.S. FDA has granted fast track designation to its experimental drug eRapa, which is the oral tablet formulation of the drug rapamycin** eRapa is being developed for the treatment of familial adenomatous polyposis, a rare, inherited..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* U.S.-listed shares of UK-based drugmaker Biodexa's , rise 57% to $6.50

\*\* Company says U.S. FDA has granted fast track designation to its experimental drug eRapa, which is the oral tablet formulation of the drug rapamycin

\*\* eRapa is being developed for the treatment of familial adenomatous polyposis, a rare, inherited condition that causes extra tissue or polyps to form in the large intestine and rectum

\*\* The FDA's "Fast Track" program is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need

\*\* Stock fell 80.2% in 2024

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P11HE:0-biodexa-rises-on-fda-s-fast-track-tag-for-rare-disease-drug/)
